Sybrand Pretorius - PAREXEL International Senior Vice President Chief Scientific Officer

PRXL -- USA Stock  

null 88.06  0.04  0.0454%

Dr. Sybrand Pretorius, M.D. is Senior Vice President, Chief Scientific Officer of the Company. He is responsible for the overall leadership of a number of the Companys business units, including Global Early Phase, Global Medical Services, Quantitative Clinical Development, and Genomic Medicine. From July 2014 to August 2016, he served as Chief Scientific Officer of the Company. From July 2010 to July 2014, he served as Corporationrationrate Vice President and Worldwide Head of Early Phase with the Company. Prior to this, he served in a number of roles with the Company, including Corporationrationrate Vice President, Worldwide Head of Clinical Operations, and Vice President, Clinical Pharmacology
Age: 45  President Since 2016      
781 487-9900
Pretorius is a medical doctor, and holds an M.B./Ch.B degree and a master?s degree in Pharmacology from the University of the Free State, South Africa, a master?s degrees in Business Administration from Potchefstroom University, South Africa, and in Management of Drug Development from the University of Southern California.

Management Efficiency

The company has return on total asset (ROA) of 6.72 % which means that it generated profit of $6.72 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 16.93 % meaning that it created $16.93 on every $100 dollars invested by stockholders.
The company currently holds 671.5M in liabilities with Debt to Equity (D/E) ratio of 105.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PAREXEL International has Current Ratio of 1.42 which is within standard range for the sector.

Similar Executives

Showing few of many executives


Marc CouckePerrigo Company plc
John GrayVertex Pharmaceuticals Incorpor
Cartikeya ReddyDr Reddys Laboratories Ltd
James DillardPerrigo Company plc
James MichaudPerrigo Company plc
Reshma KewalramaniVertex Pharmaceuticals Incorpor
Jay MarkowitzRegeneron Pharmaceuticals
Catherine KnuppZoetis
Christopher FenimoreRegeneron Pharmaceuticals
Alejandro BernalZoetis
Paul WeningerPerrigo Company plc
George YancopoulosRegeneron Pharmaceuticals
Paul SilvaVertex Pharmaceuticals Incorpor
Jing LiSinovac Biotech Ltd
Joyce LeeZoetis
Daniel PlewRegeneron Pharmaceuticals
J RamachandranDr Reddys Laboratories Ltd
Michael AbermanRegeneron Pharmaceuticals
Qiang GaoSinovac Biotech Ltd
Charles MilsteinVertex Pharmaceuticals Incorpor
Thomas FarringtonPerrigo Company plc

Entity Summary

PAREXEL International Corporationration, a biopharmaceutical services company, offer clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology solutions and services for pharmaceutical, biotechnology, and medical device industries worldwide. PAREXEL International Corp (PRXL) is traded on NASDAQ in USA and employs 18,600 people.

PAREXEL International Leadership Team

Michelle Graham, Chief Human Resource Officer, Senior Vice President
Ulf Schneider, Chief Administrative Officer, Senior Vice President
Thomas Senderovitz, Senior Vice President - Clinical Research Services
Dana Callow, Presiding Independent Director
Emma Reeve, Interim CFO, Corporate Vice President Controller
Josef Rickenbach, Founder, Chairman and CEO
Patrick Fortune, Independent Director
Eduard Holdener, Independent Director
Simon Harford, CFO, Senior Vice President
Joshua Schultz, Senior Vice President-Worldwide Head of PAREXEL Access
Gadi Saarony, Senior Vice President - Clinical Research Services
Ellen Zane, Director, Member of Compensation Committee, Member of HR Committee, CEO of Tufts Medical Center and President of Tufts Medical Center
Christian Dreger, Senior Vice President - Parexel Access and Parexel Consulting
Xavier Flinois, President - Perceptive Informatics
Douglas Batt, Sr. VP, General Counsel and Secretary
Sybrand Pretorius, Senior Vice President Chief Scientific Officer
Maykin Ho, Director
Richard Love, Independent Director
Ronald Aldridge, Sr. Director, Investor Relations
Mark Goldberg, President COO
Roland Andersson, Senior Vice President - Clinical Research Services
Christopher Lindop, Independent Director
Ingo Bank, CFO and Sr. VP
David Godwin, Senior Vice President-Global Business

Stock Performance Indicators

Current Sentiment - PRXL

PAREXEL International Investor Sentiment

Most of Macroaxis users are at this time bullish on PAREXEL International Corp. What is your perspective on investing in PAREXEL International Corp? Are you bullish or bearish?
98% Bullish
2% Bearish

Currently Active Assets on Macroaxis

Purchased over 70 shares of
a day ago
Traded for 36.96
Purchased over 40 shares of
a day ago
Traded for 62.36
Purchased over 70 shares of
a day ago
Traded for 36.96
Purchased few shares of
a day ago
Traded for 175.71
Purchased a lot of shares of
a day ago
Traded for 152.04
Additionally take a look at Your Equity Center. Please also try Bollinger Bands module to use bollinger bands indicator to analyze target price for a given investing horizon.